Corporate | 8 November 2005 07:24

Eckert & Ziegler, 3rd Quarter: Sales Increase by 19%, EBT by 65%.

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Eckert & Ziegler, 3rd Quarter: Sales Increase by 19%, EBT by 65%. Berlin, 08.11.2005. Eckert & Ziegler AG (ISIN DE0005659700), a specialist for radiation related products for the treatment of cancer and nuclear imaging could close the third quarter 2005 with good results. Cumulative sales of 30 million EUR over the first nine months represented an increase of about 19% over the same period of last year. Earnings before taxes from continuing operations (EBT) rose by 65% to 1.9 million EUR, so that a net income of 0.29 EUR per share was posted for the period ending September 30, 2005. Without the integration costs of the newly acquired divisions the figure would have been approximately 0.49 EUR per share. The greatest increase was shown by the Nuclear Medicine & Industry segment, with sales of 18.1 million EUR, or about 22% more than in the same period of last year. A large part of this rise derives from the products of newly aquired companies in Europe and the USA. The sales in the Therapy segment rose by approximately 15% to 11.9 million EUR. For the financial year 2005 the Board expects sales of more than 40 million EUR and an earning per share of approximately 0.50 EUR. The complete quarterly report III/2005 can be viewed at www.ezag.de. The Executive Board Your contact for enquiries: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, D-13125 Berlin Tel.: +49 (0) 30 / 94 10 84-138 http://www.ezag.de End of announcement (c)DGAP 08.11.2005 —————————————————————————— WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart